Navigation Links
Anesiva Initiates Phase 2 Trial with Adlea(TM) for Pain Relief Following Total Hip Replacement Surgery
Date:10/4/2007

Adlea May Provide Pain Relief Without Opiate-Like Side Effects For Weeks to

Months Following a Single Administration

SOUTH SAN FRANCISCO, Calif., Oct. 4 /PRNewswire-FirstCall/ -- Anesiva, Inc. (Nasdaq: ANSV) today announced that the first patient has been treated in a Phase 2 study of the company's compound Adlea(TM) (formerly 4975) for post-operative pain in patients who undergo total hip replacement surgery, also called Total Hip Arthroplasty (THA). Adlea is a long-acting, non-opiate analgesic drug candidate designed to provide pain relief for weeks to months after a single local application during the surgical procedure.

"Hip replacement surgery can involve a long recovery time -- sometimes up to six months -- which is frequently accompanied by post-operative pain from the procedure," said John P. McLaughlin, chief executive officer of Anesiva. "We believe Adlea may help alleviate the resulting pain for patients without the troubling side effects that other treatments such as opiates and COX-2 inhibitors can cause. We believe that these benefits can help patients recover faster and complete their rehabilitation more successfully after surgery."

The trial will enroll approximately 160 patients, randomized to receive either a single 15-mg dose of Adlea or placebo instilled into the surgical wound prior to closure. The trial will evaluate safety, tolerability, pharmacokinetics, and the ability of Adlea to reduce post-operative pain following total hip replacement surgery.

Anesiva previously announced positive data from a Phase 2 study showing that a single treatment with Adlea in patients undergoing total knee replacement surgeries produced significant reduction in pain on ambu
'/>"/>

SOURCE Anesiva, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Anesiva Announces Phase 2 Data Showing Substantial, Long-Term Pain Reductions with Adlea(TM) (formerly 4975) in Osteoarthritis of the Knee
2. Malvern initiates European user group meetings for chemical imaging
3. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
4. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...-NuVasive,Inc.(Nasdaq: NUVA ),amedicaldevicecompan...surgicaltreatmentsforthespine,announcedtodaythatit...5:30p.m.ET/2:30p.m.PT.Theconferencecallwillfocuson...sproductsandwillincludecommentsfrommanagementfollo...ersare1-877-407-4018fordomesticcallersand1-201-689...
(Date:11/25/2009)...er.comannouncesthatanewmarketresearchreportisavail...USMarketTrends&Analysis http://www.reportlink...et-Trends--Analysis.html ,, TheUSintranasaldru...capplicationsfromthedeliveryofconventionallocalthe...gs.Thefutureofthetechnologyhingesontotheeffectivee...
(Date:11/25/2009)...-- ChemoCentryx,Inc.,announcedtodaythatPhaseII/II...iveRandomizedOralTherapyEvaluationinCrohn,sdisease...erate-to-severeCrohn,sdiseasedemonstratedclinicale...Thestudydemonstratedevidenceofclinicalefficacyinth...reaseintheCrohn,sDiseaseActivityIndex(CDAI)inpatie...
Breaking Medicine Technology:NuVasive Announces Conference Call and Webcast Regarding Reimbursement 2NuVasive Announces Conference Call and Webcast Regarding Reimbursement 3Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 2Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 3Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 4Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 5ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 2ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 3ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 4ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 5LSUHSC research identifies enzyme that makes survival molecule for key vision cells 50167 1LSUHSC research identifies enzyme that makes survival molecule for key vision cells 50167 2Taxpayer Alliance applauds bill to broaden access to federal research results 9018 1Taxpayer Alliance applauds bill to broaden access to federal research results 9018 2T STAR grant funds genetic studies on shrimp and papaya and endangered cycad rescue 9016 1T STAR grant funds genetic studies on shrimp and papaya and endangered cycad rescue 9016 2
...ELBOURNE, Australia, Sept. 4 Cytopia Limited (ASX...ment for its Phase Ib/II,study of CYT997, the comp...n patients with an aggressive form of brain cancer... clinical trial is the first Phase II efficacy stu... the company and the second in its,suite of Phase ...
...nother Roche first in TaqMan(R) real-time PCR test... lab, PLEASANTON, Calif., Sept. 4 The U.S. ...Roche COBAS(R) TaqMan(R) HBV Test,the first assay ... the U.S.,The test uses Roche,s real-time PCR tech... DNA in a patient,s blood. Doctors may use viral l...
Other Medicine Technology:Cytopia Commences Second Phase II Study in Brain Cancer 2Cytopia Commences Second Phase II Study in Brain Cancer 3FDA Approves First Hepatitis B Viral Load Test 2FDA Approves First Hepatitis B Viral Load Test 3
(Date:11/25/2009)...tiative expands to include cost-effective, sustain... healthcare professionals in developing world. , ...ember 25, 2009 -- Elluminate, Inc. , the leader i...ns that support 21st century teaching, learning, ...and Ice initiative was awarded iNACOL,s first-ev...
(Date:11/25/2009)...RNewswire/--dazzlesmile,llc www.dazzlesmile.com an....com havefileda67-pagefederallawsuitagainstEpicAdv...ms,FarendServicesLimited,andAtLastFulfillment.The1...ourtfortheDistrictofUtah,allegesmassivenationalcon...eethwhiteningproducts,violationsoftheRacketeeringI...
(Date:11/25/2009)...in French and Spanish . , , Researchers... early diagnosis of certain ocular diseases that a...degeneration and keratitis, by applying an existin...before been used for this purpose. , Scientists ...ubjects affected by one of these two pathologies, ...
(Date:11/25/2009)...icians at UT Southwestern Medical Center soon will... breathing in patients with upper spinal-cord inju...ng independently. , UT Southwestern University ...n Texas and one of 25 in the country currently equ...hragm Pacing System. , The device is designed to...
(Date:11/25/2009)...ing support for recent enforcement actions against...sociation of Chain Drug Stores (NACDS) submitted a... The letter expresses the Association’s con... foreign, that are engaged in a pattern of illegal... of prescription medications. , ...
Breaking Medicine News(10 mins):Health News:Elluminate's Fire and Ice Project Recognized as First-Ever iNACOL Award Winner for Outstanding and Most Innovative Online Learning Practice 2Health News:Elluminate's Fire and Ice Project Recognized as First-Ever iNACOL Award Winner for Outstanding and Most Innovative Online Learning Practice 3Health News:Elluminate's Fire and Ice Project Recognized as First-Ever iNACOL Award Winner for Outstanding and Most Innovative Online Learning Practice 4Health News:Elluminate's Fire and Ice Project Recognized as First-Ever iNACOL Award Winner for Outstanding and Most Innovative Online Learning Practice 5Health News:dazzlesmile Sues Epic Advertising and Jesse Willms 2Health News:Achieve early diagnosis of ocular pathologies such as keratitis and macular degeneration 2Health News:New device implanted by surgeons help paralyzed patients breathe easier 2Health News:NACDS Supports FDA Enforcement Against Rogue Internet Pharmacy Websites 2
...ld Lester Boggs whose lackadaisical attitude towar... the cause of his death// when he apparently expos...n Sept. 3 at St. John's Hospital marking Sangamon ...virus. Boggs' wife of 66 years, Mary Boggs, ...
...officials have announced a hike of 5.6 percent for...ides this premiums for the wealthier// beneficiari...rst time the federal government has required the a...vering doctor visits and outpatient hospital care,...
... to a Japanese study, there has been a significant...ases, due to drinking of green tea//. A 25 ...sease was reported in this study conducted on more...the diet in the west. The findings of this...
...inflammatory drug colchicine, which is often used ...preventing liver cancer// in patients with hepatit...researchers said in a new study. The study f... the Instituto Nacional de Cancerologia, Mexico Ci...
...he safest pain medication? Many people with osteoa...r studies linked the painkillers called COX-2 inhi...le with arthritis have switched from a COX-2 drug ...ctive at reducing pain and inflammation, they can ...
...vation issue continues to haunt the prestigious Al... as the main poll plank// for the elections to its...ly Tuesday. Nearly 1,400 resident doctors, in... Sixteen Candidates are contesting the elections t...
Other Medicine News:Health News:91-year-old city man Falls Victim to West Nile Virus 2Health News:Medicare Premiums to be Higher Next Year 2Health News:Live long with Green tea!! 2Health News:Live long with Green tea!! 3Health News:AIIMS Goes to Polls Amid Reservation Issues 2
Full Handle Laseredge Implant Blade Knife, 3.2 mm round tip
Full Handle Laseredge Implant Blade Knife, 5.2 mm angled bevel up
Full Handle Laseredge Implant Blade Knife, 4.0 mm angled bevel up
Full Handle Laseredge Crescent Blade Knife, angled bevel down
Medicine Products: